摘要
目的:了解全国胰岛素药物市场的现状、市场发展的影响因素等.方法:根据14城市1998～2001年近300家医院用药数据进行分析.结果:目前全国胰岛素市场规模约4亿元,年平均增长率为24.4%;基因胰岛素平均增长率为56.6%,快速挤压动物胰岛素,目前已占60%以上市场份额;市场集中度有快速向外资品牌集中的趋势(已占60%以上);中效胰岛素的需求占2/3以上;400U/10ml×1为主流规格.未来几年胰岛素市场将会以10%～20%的幅度增长,短期内基因胰岛素继续替代动物胰岛素,从长远看则非注射型精确释药人胰岛素更有发展前途.结论:市场已高度集中,不应轻易介入基因胰岛素,而应研发新剂型.
Objective:To study the insulin market situation in China and its influence factors. Methods:Insulin sale data collected from about 300 sample hospitals of 14 cities from 1998 to 2001 was analysed. Results:(a)Insulin sale could reach RMB $400 million in China, the average annual growth rate of insulin was 24.4%, and the growth rate of gene insulin was 56.6%, the market share of gene insulin was more than 60%. The market share had been more and more concerntrating on foreign brand products ( its market share was more than 60%) . The market share of middle-acting insulin was about 2/3 (66%). The main specification and package for market requirement was 400U/10ml×1. (b) In the near coming several years, the growth rate of insulin will be 10%～20%. There is a trend that insulin from animals will be replaced continually by gene insulin in a short period, while in the view of a long period, non-injection accurate release human insulin will be more attractive. Conclusion:Insulin market in China has been highly concentrated. It is not necessary to pay much attention to the investment of gene insulin products in a hurry. To research and develop new preparation forms of insulin products is important.
出处
《上海医药》
CAS
2002年第4期173-180,共8页
Shanghai Medical & Pharmaceutical Journal
